IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1206 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2070    
    Printed88    
    Emailed2    
    PDF Downloaded204    
    Comments [Add]    

Recommend this journal

 

 SHORT COMMUNICATION
Year : 2011  |  Volume : 43  |  Issue : 4  |  Page : 463-465

A comparative study of efficacy and safety of arformoterol and salbutamol nebulization as rescue therapy in acute non-severe asthma


1 Department of Respiratory Medicine, North Bengal Medical College, Sushrutanagar, Darjeeling - 734 012, West Bengal, India
2 Department of Pharmacology, North Bengal Medical College, Sushrutanagar, Darjeeling - 734 012, West Bengal, India
3 Department of Ophthalmology, North Bengal Medical College, Sushrutanagar, Darjeeling - 734 012, West Bengal, India

Correspondence Address:
Sibes K Das
Department of Respiratory Medicine, North Bengal Medical College, Sushrutanagar, Darjeeling - 734 012, West Bengal
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0253-7613.83123

Rights and Permissions

Arformoterol, a long-acting beta-2 agonist, has a rapid onset and long duration of action. Its role as rescue medication in acute asthma attack is undetermined. To compare the efficacy and tolerability of arformoterol with salbutamol nebulization, a study was conducted among 50 patients with acute non-severe asthma. Patients were randomly assigned to group 1 (n = 25) and group 2 (n = 25) who received three doses of salbutamol and arformoterol nebulization, respectively, at 20-min intervals. The peak expiratory flow rate (PEFR) was measured at the baseline and 5 min after each dose. The demographics and baseline characteristics were comparable between the two groups. The mean PEFR significantly increased in both these groups when compared with the baseline. The increases in the PEFR in two groups were similar after the third dose. The adverse effects in both these groups were minor. Arformoterol was as effective and safe as salbutamol in acute non-severe asthma.






[FULL TEXT] [PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow